T. Goddemeier

发表

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

Robert Pirker, K. O'Byrne, Keunchil Park, 2009, The Lancet.

Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck

T. Brümmendorf, J. Machiels, J. Delord, 2013, Investigational New Drugs.

Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid tumors

K. Muro, K. Chìn, Ken Kato, 2018, Cancer science.

Simple-to-use, reference criteria for revealing drug-induced QT interval prolongation in conscious dogs.

I. Cavero, T. Goddemeier, F. von Landenberg, 2007, European journal of pharmacology.

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

A. Tutt, R. Plummer, G. Shapiro, 2022, NPJ breast cancer.

A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.

R. Plummer, C. Redfern, G. Shapiro, 2021, Lung cancer.

Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

C. Nutting, S. Rottey, A. Bexon, 2014, Investigational New Drugs.

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.

K. O'Byrne, F. de Marinis, J. von Pawel, 2011, The Lancet. Oncology.

Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study.

K. O'Byrne, Keunchil Park, F. de Marinis, 2012, Lung cancer.

Height growth of adolescent German boys and girls.

F. Manz, T. Goddemeier, T. Wember, 1992, Annals of human biology.

A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors.

A. Tolcher, T. Yap, J. Bono, 2021 .

Phase I dose-escalation trial of Sym004, a mixture of two anti-EGFR antibodies, in Japanese patients with advanced solid tumors.

K. Muro, Ken Kato, T. Doi, 2016 .

Practical implementation of the partial ordering continual reassessment method in a Phase I combination‐schedule dose‐finding trial

T. Jaki, P. Mozgunov, T. Goddemeier, 2022, Statistics in medicine.

A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours.

J. Bolleddula, M. Lolkema, H. Burris, 2024, British journal of cancer.

Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study.

K. O'Byrne, Keunchil Park, R. Ramlau, 2012, Lung cancer.